Skip to content

Patient voice — lung squamous-cell carcinoma

This directory preserves the lived-experience evidence behind the wiki page on patient experience and advocacy. LUSC-specific qualitative evidence is sparse, so the layer distinguishes direct squamous evidence from evidence involving mixed-histology lung cancer or NSCLC. Smoking stigma and central-airway symptoms make some experiences especially salient in LUSC, but they are not exclusive to it.

Files

File Contents
themes.md Evidence-backed synthesis of diagnosis, stigma, symptoms, decisions, caregiving, financial toxicity, trials, palliative care, and survivorship
sources.md Annotated research and public-source inventory, with provenance and coverage limits
organizations.md Verified patient-support and advocacy organizations and the functions they provide

The clinical synthesis is at patient experience and advocacy.

Methodology — sessions of 2026-08-29 and 2026-08-30

Published evidence was found through live PubMed E-utilities searches combining lung cancer or NSCLC with qualitative research, patient experience, diagnostic delay, stigma, communication, patient-reported outcomes, caregiver burden, financial toxicity, unmet needs, clinical-trial participation, palliative care, and survivorship. Every PMID in this layer was returned by a live PubMed query in this session and then included in the condition-wide ESummary re-query.

Public organizational pages were re-fetched from the organizations' own domains on 2026-08-30. The layer records services and advocacy infrastructure, not endorsements. Availability, eligibility, languages, opening hours, and geographic reach can change and must be re-checked before referral.

Ethics and synthesis rules

  1. Use public material only; no closed forums, private groups, or logged-in communities.
  2. Paraphrase rather than harvest stories. This layer contains no composite or invented quotations.
  3. Do not name or combine details about private individuals.
  4. Promote an experience to a theme only when supported by at least two independent sources or by a synthesis plus a compatible primary study.
  5. Label mixed-histology evidence. Do not imply that an NSCLC-wide experience is uniquely squamous.
  6. Treat patient-reported outcomes as outcomes, not decoration; retain instruments, time points, denominators, and uncertainty where available.
  7. Keep urgent clinical safety advice in the wiki red-flags page, not in patient testimony.

Coverage limits

  • Most retrieved studies were from North America, Europe, Australia, or East Asia; low- and middle-income settings are underrepresented.
  • Many studies enrolled "lung cancer" or NSCLC without reporting a LUSC subgroup.
  • People too unwell to participate, those without digital access, people with low literacy, and bereaved families may be systematically under-sampled.
  • Qualitative saturation does not establish prevalence. Survey prevalence depends on the instrument and sampling frame.
  • Organizational stories can be selected for advocacy or fundraising aims and are not treated as epidemiological samples.
  • Treatment-era changes matter: experiences predating immunotherapy may not capture prolonged maintenance, immune toxicity, or biomarker-related uncertainty.

Updating this layer

Re-run PubMed searches, re-fetch organizational pages, add new sources to sources.md, and change themes.md only when the new material strengthens, contradicts, or adds a theme. Propagate material changes to the wiki page and record the update in the condition log.